Posted by Michael Wonder on 06 Dec 2022
ICER identifies most significant 2021 US drug price hikes unsupported by new clinical evidence
6 December 2022 - Seven out of 10 high expenditure drugs had substantial 2021 net price increases that were not supported by new clinical evidence; these increases accounted for $805 million in additional costs over one year.
The ICER today published its latest report on unsupported price increases of prescription drugs in the United States.
